Objective:

To correct references related to the prognostic significance of 1q21 chromosomal abnormalities in multiple myeloma.

Approach:

• Reference Corrections: The article provides corrections for multiple references that were inaccurately cited in the original publication.

Key Findings:

• Reference 5 corrected to reflect accurate authorship and details regarding CKS1B amplification.
• Reference 20 corrected to clarify the significance of intraclonal heterogeneity in myeloma.
• Reference 21 corrected to specify the heterogeneity of genomic evolution in multiple myeloma.
• Reference 22 corrected to combine chromosomal aberrations with the International Staging System.
• Reference 23 corrected to define a poor prognostic subgroup of hyperdiploid multiple myeloma.
• Reference 24 corrected to identify ultra high-risk myeloma with prognostic implications.
• Reference 27 corrected to specify results from the HOVON-65/GMMG-HD4 trial.
• Reference 30 corrected to provide accurate guidelines for therapy in relapsed multiple myeloma.

Interpretation:

The corrections ensure that the references accurately reflect the findings and contributions of the cited works.

Limitations:

• The article does not discuss new findings or data beyond the corrections of references.

Conclusion:

The corrections enhance the accuracy of the literature on the prognostic importance of 1q21 chromosomal abnormalities in multiple myeloma.